{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T23:41:31Z","timestamp":1762386091399,"version":"build-2065373602"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Genetic Counseling"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Duchenne muscular dystrophy (DMD) is an X\u2010linked genetic condition characterized by progressive muscle degeneration. Recently, several genotype\u2010specific treatment options for DMD have become available. Prenatal genetic counselors may encounter at\u2010risk patients for DMD, through a variety of indications. However, little is known about how prenatal genetic counselors approach conversations about these emerging treatment options. This study aims to explore prenatal genetic counselors' attitudes, beliefs, and practices in discussing postnatal DMD treatment options with their patients. Board\u2010certified genetic counselors providing preconception or prenatal care in the United States were eligible to participate. Individuals were recruited via convenience sampling through two professional genetic counseling organization listservs. Purposive sampling was used to select 12 individuals with diverse experiences and perspectives, who participated in one\u2010on\u2010one, semistructured Zoom interviews. Topics included the practices of prenatal genetic counselors related to DMD using clinical vignettes; DMD treatment knowledge; and attitudes and beliefs about DMD treatments. Data were transcribed, coded, and analyzed using reflexive thematic analysis. Three themes, one with two subthemes, were produced: (1) discussing DMD treatments in the prenatal setting is highly tailored; (2) discussing DMD treatments with prenatal patients is critical to informed decision making, with subthemes (2a) information about DMD treatments should be balanced and accurate, and (2b) multidisciplinary teams, including prenatal genetic counselors, should support patients in navigating DMD treatment discussions; and (3) prenatal genetic counselors need concise and updated resources relating to DMD treatments. These findings indicate that prenatal genetic counselors play an important role in patients' health care teams when considering DMD treatments. They also emphasize the importance of prenatal genetic counselors staying updated with advancements in treatments and communicating information to patients accurately and in a balanced manner. Given the nuanced nature of these discussions, practice guidelines may be needed.<\/jats:p>","DOI":"10.1002\/jgc4.70127","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T23:38:45Z","timestamp":1762385925000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prenatal genetic counselors' attitudes, beliefs, and practices with discussing postnatal Duchenne muscular dystrophy treatment options"],"prefix":"10.1002","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3866-2704","authenticated-orcid":false,"given":"Shawna L.","family":"Jurlina","sequence":"first","affiliation":[{"name":"Department of Human Genetics, David Geffen School of Medicine University of California, Los Angeles  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Gorman","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, David Geffen School of Medicine University of California, Los Angeles  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina G. S.","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, David Geffen School of Medicine University of California, Los Angeles  Los Angeles California USA"},{"name":"Department of Psychiatry and Biobehavioral Sciences University of California, Los Angeles  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca LeShay","family":"Araujo","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, David Geffen School of Medicine University of California, Los Angeles  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2020.0845"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0657"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20586"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001952"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040912"},{"key":"e_1_2_12_7_1","volume-title":"Successful qualitative research: A practical guide for beginners","author":"Braun V.","year":"2013"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1037\/qup0000196"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/02692163241234800"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24332"},{"key":"e_1_2_12_11_1","unstructured":"Certified Duchenne Care Center. (n.d.).Find a Certified Duchenne Care Center. Retrieved September 17 2025 fromhttps:\/\/www.parentprojectmd.org\/care\/find\u2010a\u2010certified\u2010duchenne\u2010care\u2010center\/"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264"},{"key":"e_1_2_12_13_1","unstructured":"Darras B. Shefner J. &Dashe J.(2024).Duchenne and Becker muscular dystrophy: Glucocorticoid and disease\u2010modifying treatment.https:\/\/www.uptodate.com\/contents\/duchenne\u2010and\u2010becker\u2010muscular\u2010dystrophy\u2010glucocorticoid\u2010and\u2010disease\u2010modifying\u2010treatment"},{"key":"e_1_2_12_14_1","volume-title":"GeneReviews\u00ae","author":"Darras B. T.","year":"1993"},{"key":"e_1_2_12_15_1","unstructured":"Department of Health and Human Services. (2016).US Food and Drug Administration. Center for Drug Evaluation and Research.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2016\/206488Orig1s000ltr.pdf"},{"key":"e_1_2_12_16_1","unstructured":"Department of Health and Human Services. (2019).US Food and Drug Administration. Center for Drug Evaluation and Research.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/211970Orig1s000ltr.pdf"},{"key":"e_1_2_12_17_1","unstructured":"Department of Health and Human Services. (2020).US Food and Drug Administration. Center for Drug Evaluation and Research.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2020\/212154Orig1s000ltr.pdf"},{"key":"e_1_2_12_18_1","unstructured":"Department of Health and Human Services. (2021).US Food and Drug Administration. Center for Drug Evaluation and Research.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/213026Orig1s000ltr.pdf"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010021\u201000248\u20103"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.58347\/tml.2023.1686d"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10897\u2010016\u20109978\u20101"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009233"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41431\u2010020\u20100643\u20107"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436\u2010021\u201001203\u2010z"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND\u2010180351"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/life13071545"},{"key":"e_1_2_12_27_1","unstructured":"Meglio M.(2024 November 5).FDA accepts resubmitted NDA for ataluren in nonsense Duchenne muscular dystrophy.NeurologyLive.https:\/\/www.neurologylive.com\/view\/fda\u2010accepts\u2010resubmitted\u2010nda\u2010ataluren\u2010nonsense\u2010duchenne\u2010muscular\u2010dystrophy"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24555"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003304\u2010z"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23982"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1167762"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010023\u201011687\u20101"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1276144"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.1892"},{"key":"e_1_2_12_35_1","unstructured":"Professional Status Survey. (2024).National Society of Genetic Counselors.https:\/\/www.nsgc.org\/Policy\u2010Research\u2010and\u2010Publications\/Professional\u2010Status\u2010Survey"},{"key":"e_1_2_12_36_1","unstructured":"PTC Therapeutics. (n.d.).Study of Ataluren in previously treated participants with nonsense\u2010mutation dystrophinopathy (PTC124\u2010GD\u2010016 DMD).https:\/\/clinicaltrials.ptcbio.com\/trials\/PTC124\u2010GD\u2010016%20DMD"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010017\u20100631\u20103"},{"key":"e_1_2_12_38_1","unstructured":"Sarepta Therapeutics Inc. (2024a).Creating a treatment plan for Duchenne muscular dystrophy. VYONDYS 53.https:\/\/www.vyondys53.com\/starting\u2010treatment\/make\u2010treatment\u2010plan"},{"key":"e_1_2_12_39_1","unstructured":"Sarepta Therapeutics Inc. (2024b).Plan for treatment of Duchenne muscular dystrophy.https:\/\/www.exondys51.com\/starting\u2010treatment\/make\u2010treatment\u2010plan"},{"key":"e_1_2_12_40_1","unstructured":"Sarepta Therapeutics Inc. (2025a).DMD treatment plan: Planning for treatment.https:\/\/www.amondys45.com\/starting\u2010treatment\/planning\u2010for\u2010treatment"},{"key":"e_1_2_12_41_1","unstructured":"Sarepta Therapeutics Inc. (2025b).ELEVIDYS (delandistrogene moxeparvovec\u2010rokl) for healthcare professionals.https:\/\/www.elevidyshcp.com\/"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2021.0043"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20976"},{"key":"e_1_2_12_44_1","volume-title":"ELEVIDYS (delandistrogene moxeparvovec\u2010rokl) [Package insert]","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"e_1_2_12_45_1","unstructured":"US Food and Drug Administration. Center for Biologics Evaluation and Research. (2023).June 22 2023 Approval Letter\u2014ELEVIDYS.https:\/\/www.fda.gov\/media\/169715\/download"},{"key":"e_1_2_12_46_1","unstructured":"US Food and Drug Administration. Center for Biologics Evaluation and Research. (2024).June 20 2024 Approval Letter\u2014ELEVIDYS.https:\/\/www.fda.gov\/media\/179484\/download?utm_source=chatgpt.com"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.1932"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010024\u201002801\u20104"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.1953"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2021.57.12.3352740"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.1549"}],"container-title":["Journal of Genetic Counseling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgc4.70127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T23:38:48Z","timestamp":1762385928000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jgc4.70127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/jgc4.70127"],"URL":"https:\/\/doi.org\/10.1002\/jgc4.70127","archive":["Portico"],"relation":{},"ISSN":["1059-7700","1573-3599"],"issn-type":[{"value":"1059-7700","type":"print"},{"value":"1573-3599","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"2025-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70127"}}